In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
|Slideshows|May 7, 2020
5 Tips for Treating COVID-Related Anxiety
Author(s)Yujuan Choy, MD
A constellation of factors contributes to heightened anxiety symptoms associated with the pandemic. The author offers simple steps to help patients alleviate stress.
Advertisement
Advertisement
Related to this article
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Promoting Literacy to Improve Child Development: Reading Model Boosts Efforts
5